Browse > Article

Effect of Lipofectin on Antigen-presenting Function and Anti-tumor Activity of Dendritic Cells  

Noh, Young-Woock (Department of Biological Sciences, Sookmyung Women's University)
Lim, Jong-Seok (Department of Biological Sciences, Sookmyung Women's University)
Publication Information
IMMUNE NETWORK / v.6, no.2, 2006 , pp. 102-110 More about this Journal
Abstract
Background: Dendritic cells (DC) are professional antigen-presenting cells in the immune system and can induce T cell response against virus infections, microbial pathogens, and tumors. Therefore, immunization using DC loaded with tumor-associated antigens (TAAs) is a powerful method of inducing anti-tumor immunity. For induction of effective anti-tumor immunity, antigens should be efficiently introduced into DC and presented on MHC class I molecules at high levels to activate antigen-specific $CD8^+$ T cells. We have been exploring methods for loading exogenous antigens into APC with high efficiency of Ag presentation. In this study, we tested the effect of the cationic liposome (Lipofectin) for transferring and loading exogenous model antigen (OVA protein) into BM-DC. Methods: Bone marrow-derived DC (EM-DC) were incubated with OVA-Lipofectin complexes and then co-cultured with B3Z cells. B3Z activation, which is expressed as the amount of ${\beta}$-galactosidase induced by TCR stimulation, was determined by an enzymatic assay using ${\beta}$-gal assay system. C57BL/6 mice were immunized with OVA-pulsed DC to monitor the in vivo vaccination effect. After vaccination, mice were inoculated with EG7-OVA tumor cells. Results: BM-DC pulsed with OVA-Lipofectin complexes showed more efficient presentation of OVA-peptide on MHC class I molecules than soluble OVA-pulsed DC. OVA-Lipofectin complexes-pulsed DC pretreated with an inhibitor of MHC class I-mediated antigen presentation, brefeldin A, showed reduced ability in presenting OVA peptide on their surface MHC class I molecules. Finally, immunization of OVA-Lipofectin complexes-pulsed DC protected mice against subsequent tumor challenge. Conclusion: Our data provide evidence that antigen-loading into DC using Lipofectin can promote MHC class I- restricted antigen presentation. Therefore, antigen-loading into DC using Lipofectin can be one of several useful tools for achieving efficient induction of antigen-specific immunity in DC-based immunotherapy.
Keywords
Dendritic cell; DC-based immunotherapy; lipofectin; antigen presentation; anti-tumor immunity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Nouri-Shirazi M, Banchereau J, Fay J, Palucka K: Dendritic cell based tumor vaccines. Immunol Letter 74;5-10, 2000   DOI   ScienceOn
2 Karttunen J, Sanderson S, Shastri N: Detection of rare antigenpresenting cells by the LacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89;6020-6024, 1992
3 Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156;2918-2926, 1996
4 De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K: Retrovirally transduced bone marrow-derived dendritic cells require $CD4^+$ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162; 144-151, 1999
5 Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C: Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27;280-288, 1997
6 Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1;362-368, 1999   DOI   ScienceOn
7 Nakanishi T, Hayashi A, Kunisawa J, Tsutsumi Y, Tanaka K, Yashiro-Ohtani Y, Nakanishi M, Fujiwara H, Hamaoka T, Mayumi T: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 30;1740-1747, 2000   DOI   ScienceOn
8 Eriksson K, Sun JB, Nordstrom I, Fredriksson M, Lindblad M, Li BL, Holmgren J: Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur J Immunol 34;1272-1281, 2004   DOI   ScienceOn
9 Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18;767-811, 2000   DOI   ScienceOn
10 Shen Z, Reznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
11 Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101; 977-982, 2003   DOI   ScienceOn
12 Shen Z, Renznikoff G, Dranoff G, Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158;2723-2730, 1997
13 Shastri N, Gonzalez F: Endogenous generation and presentation of the ovalbumin peptide/k(b) complex to T-cells. J Immunol 150;2724-2736, 1993
14 Moore MW, Carbone FR, Bevan MJ: Introduction of solubleprotein into the class-I pathway of antigen processing and presentation. Cell 54;777-785, 1988   DOI   ScienceOn
15 Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182;389-400, 1995   DOI   ScienceOn
16 Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A: Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 84;1564-1570, 2001   DOI   ScienceOn
17 Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998   DOI   ScienceOn
18 Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20;2287-2295, 2002   DOI   ScienceOn
19 Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD: Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother 53;315-522, 2004   DOI
20 Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90;1920-1926, 1997
21 Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15; 138-147, 2003   DOI   ScienceOn
22 Galea-Lauri J, Wells J, Darling D, Harrison P, Farzaneh F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53;963-977, 2004
23 Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med 176; 1693-1702, 1992   DOI   ScienceOn
24 Kim A, Kim KD, Choi SC, Jeong MJ, Lee HG, Choe YK, Paik SG, Lim JS: IL-12 production and subsequent natural killer cell activation by necrotic tumor cell-loaded dendritic cells in therapeutic vaccinations. Immune Network 3;188-200, 2003   DOI
25 Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10;281-287, 1999   DOI   ScienceOn
26 Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53;240-248, 2004   DOI
27 Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS: Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 36;428-443, 2004   DOI   ScienceOn